A novel, first-in-class Cannabinoid Receptor for the treatment of Post-Traumatic Stress Disorder (PTSD). This asset represents a paradigm shift in CNS therapeutics, leveraging decades of world-leading research in endocannabinoid chemistry to address a significant unmet medical need. The program is currently in the Nonclinical Phase 2 stage of development, with a clear path toward completion of IND-enabling toxicology, CMC activities, file an Investigational New Drug (IND) application with the FDA, and initiate a Phase 1 clinical study.